Table 3.

Immunohistochemical detection (ID) and RT-PCR analysis of E-cadherin and N-cadherin expression in 28 patients with transitional cell carcinoma of the bladder

CaseE-cadherin
N-cadherin
IDRT-PCRIDRT-PCR
Stage pTa
    1HeteroPosNegPos
    2PosPosNegPos
    3PosPosNegPos
    4PosPosNegNeg
    5PosPosNegNeg
    6PosPosNegPos
    7PosPosNegNeg
    8PosPosNegNeg
    9PosPosNegNeg
    10PosPosNegPos
    11PosPosNegPos
    12PosPosNegNeg
Stage pT1
    13PosPosPosPos
    14PosPosPosPos
    15HeteroPosPosPos
    16PosPosNegNeg
    17PosPosNegPos
    18PosPosPosPos
    19HeteroPosPosPos
    20HeteroPosPosPos
Stage pT2-pT3
    21HeteroPosNegPos
    22HeteroPosPosPos
    23HeteroPosPosPos
    24HeteroPosNegNeg
    25PosPosNegNeg
    26HeteroPosNegPos
    27HeteroPosNegNeg
    28HeteroPosNegNeg
  • Abbreviations: Pos, positive immunostaining/detectable band in RT-PCR analysis; Neg, negative immunostaining for N-cadherin/no detectable band in RT-PCR analysis; Hetero, heterogeneous (abnormal) immunostaining for E-cadherin.